Compare Rockwell Automation (ROK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rockwell Automation vs BIO-TECHNE Corp — how do they compare? Rockwell Automation trades at $438.29 (market cap $49.07B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Rockwell Automation is far larger — about 4.3× BIO-TECHNE Corp's market cap, and Rockwell Automation pays the higher dividend (1.25%). Which is the better fit depends on your goals — on Pluang, investors hold Rockwell Automation for 74 Days and BIO-TECHNE Corp for 63 Days on average.
| ROK | TECH | |
|---|---|---|
Market Cap | $49.07B | $11.37B |
Volume | 783,067 | 3,153,511 |
Sector | Industrials | Health |
52-Week High | $495.08 | $72.61 |
52-Week Low | $333.75 | $43.31 |
Typical Hold Time | 74 Days | 63 Days |
Enterprise Value | $52.21B | $11.40B |
Dividend Yield | 1.25% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rockwell Automation (ROK) trades at $434.14, down 3.68% on the day, with a bullish technical signal from moving averages. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue for 2025 was $8.34 billion, with a net income margin of 13.38%. Recent news highlights its leadership in industrial automation and digital transformation, including partnerships in AI-enabled cyber defense.
The outlook is supported by strong profitability and analyst consensus, but high valuation multiples and competitive pressures pose risks. The consensus price target of $489.89 suggests potential upside, though investors should monitor earnings sustainability and macroeconomic factors affecting industrial demand.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
